Collegium Pharmaceutical Past Earnings Performance
Past criteria checks 4/6
Collegium Pharmaceutical has been growing earnings at an average annual rate of 22.8%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 17.5% per year. Collegium Pharmaceutical's return on equity is 37.8%, and it has net margins of 14.8%.
Key information
22.8%
Earnings growth rate
24.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 17.5% |
| Return on equity | 37.8% |
| Net Margin | 14.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Collegium Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 599 | 89 | 157 | 0 |
| 30 Jun 24 | 577 | 100 | 154 | 0 |
| 31 Mar 24 | 567 | 93 | 148 | 0 |
| 31 Dec 23 | 567 | 48 | 151 | 0 |
| 30 Sep 23 | 547 | 9 | 156 | 0 |
| 30 Jun 23 | 537 | -11 | 159 | 0 |
| 31 Mar 23 | 525 | -29 | 158 | 0 |
| 31 Dec 22 | 464 | -25 | 142 | 4 |
| 30 Sep 22 | 362 | -43 | 127 | 6 |
| 30 Jun 22 | 314 | -35 | 119 | 7 |
| 31 Mar 22 | 273 | 43 | 113 | 11 |
| 31 Dec 21 | 277 | 72 | 119 | 9 |
| 30 Sep 21 | 326 | 104 | 119 | 10 |
| 30 Jun 21 | 326 | 107 | 115 | 11 |
| 31 Mar 21 | 321 | 42 | 114 | 10 |
| 31 Dec 20 | 310 | 27 | 114 | 10 |
| 30 Sep 20 | 308 | 18 | 112 | 10 |
| 30 Jun 20 | 302 | 0 | 116 | 10 |
| 31 Mar 20 | 299 | -13 | 115 | 10 |
| 31 Dec 19 | 297 | -23 | 116 | 10 |
| 30 Sep 19 | 296 | -11 | 122 | 10 |
| 30 Jun 19 | 293 | -22 | 125 | 10 |
| 31 Mar 19 | 291 | -30 | 128 | 9 |
| 31 Dec 18 | 280 | -39 | 127 | 9 |
| 30 Sep 18 | 218 | -66 | 120 | 9 |
| 30 Jun 18 | 160 | -62 | 109 | 9 |
| 31 Mar 18 | 90 | -70 | 100 | 9 |
| 31 Dec 17 | 28 | -75 | 91 | 9 |
| 30 Sep 17 | 19 | -85 | 93 | 10 |
| 30 Jun 17 | 7 | -98 | 94 | 11 |
| 31 Mar 17 | 4 | -102 | 92 | 13 |
| 31 Dec 16 | 2 | -94 | 81 | 15 |
| 30 Sep 16 | 0 | -76 | 63 | 13 |
| 30 Jun 16 | 0 | -59 | 46 | 13 |
| 31 Mar 16 | 0 | -40 | 28 | 11 |
| 31 Dec 15 | 0 | -20 | 19 | 8 |
| 30 Sep 15 | 0 | -15 | 12 | 9 |
| 30 Jun 15 | 0 | -13 | 7 | 11 |
| 31 Mar 15 | 0 | -12 | 4 | 13 |
| 31 Dec 14 | 0 | -21 | 3 | 15 |
Quality Earnings: 354 has a large one-off loss of $35.6M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 354's current net profit margins (14.8%) are higher than last year (1.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 354 has become profitable over the past 5 years, growing earnings by 22.8% per year.
Accelerating Growth: 354's earnings growth over the past year (882.6%) exceeds its 5-year average (22.8% per year).
Earnings vs Industry: 354 earnings growth over the past year (882.6%) exceeded the Pharmaceuticals industry 28.7%.
Return on Equity
High ROE: Whilst 354's Return on Equity (37.82%) is high, this metric is skewed due to their high level of debt.